Light Horse’s high-throughput discovery platform systematically explores complex signaling pathways to uncover novel sites of vulnerability in disease biology. By studying targets directly in their native cellular context, we maximize the potential for discoveries that translate into clinical breakthroughs. Our function-first screening approach —integrating systematic gene editing with site agnostic functional assays, and first-in-class chemistry — enables the identification of new targets and drug candidates across critical biological pathways. This versatile technology can interrogate any protein or entire pathways, revealing previously unknown functional sites and producing covalent or non-covalent ligands with therapeutic potential across multiple disease areas.
